An alternate NGS-only approach for chordoid meningioma management in hospital settings lacking clinically-validated NHERF1 IHC may segregate cases into high recurrence risk, when NF2, DDR and chromatin remodeling gene mutations are present (Figure 5, red labeling), and low recurrence risk, when mutations in other genes are detected (see Table S1). Here, NF2 is linked to Chordoid Meningioma.